source
- Rocket Pharmaceuticals sells pediatric disease priority review voucher for $180 million; Oruka eyes $500 million offeringRocket Pharmaceuticals, a New Jersey gene-therapy company, sold its priority review voucher for a rare pediatric disease to an undisclosed buyer for $180 million. The voucher was earned after the…
- Devoted Health reports first revenue decline in 2025 amid Medicare Advantage turbulenceDevoted Health, a startup offering Medicare Advantage plans, saw its revenue and membership drop in 2025, marking the first decline since it began offering plans seven years ago. The downturn refl…